Apricus Wealth’s Gilead Sciences GILD Stock Holding History

Apricus Wealth’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,285	Closed	-$239K	–	92
2021 Q4	$239K	Buy	+3,285	New	+$226K	0.21%	79

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Apricus Wealth's GILD Position: Q1 2022 in Review

Apricus Wealth sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 3,285 shares — an estimated $239K sold.

Apricus Wealth first reported a position in GILD in Q4 2021 and held it in 1 quarter. The position peaked at $239K in Q4 2021. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Apricus Wealth reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
Apricus Wealth sold 3,285 Gilead Sciences shares in Q1 2022, an estimated $239K.
Apricus Wealth first reported a position in Gilead Sciences in Q4 2021 and held it in 1 quarter.
Apricus Wealth's Gilead Sciences position peaked at $239K in Q4 2021.
1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Apricus Wealth's 13F filing for Q1 2022, filed 21 Apr 2022.